Lars Bullinger
Cited by
Cited by
Genomic aberrations and survival in chronic lymphocytic leukemia
H Döhner, S Stilgenbauer, A Benner, E Leupolt, A Kröber, L Bullinger, ...
New England Journal of Medicine 343 (26), 1910-1916, 2000
Genomic classification and prognosis in acute myeloid leukemia
E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ...
New England Journal of Medicine 374 (23), 2209-2221, 2016
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ...
New England Journal of Medicine 358 (18), 1909-1918, 2008
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia
L Bullinger, K Döhner, E Bair, S Fröhling, RF Schlenk, R Tibshirani, ...
New England Journal of Medicine 350 (16), 1605-1616, 2004
V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia
A Kröber, T Seiler, A Benner, L Bullinger, E Brückle, P Lichter, ...
Blood, The Journal of the American Society of Hematology 100 (4), 1410-1416, 2002
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
K Döhner, RF Schlenk, M Habdank, C Scholl, FG Rücker, ...
Blood 106 (12), 3740-3746, 2005
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 …
P Paschka, RF Schlenk, VI Gaidzik, M Habdank, J Krönke, L Bullinger, ...
Journal of clinical oncology 28 (22), 3636-3643, 2010
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L
KM Bernt, N Zhu, AU Sinha, S Vempati, J Faber, AV Krivtsov, Z Feng, ...
Cancer cell 20 (1), 66-78, 2011
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations
T Rausch, DTW Jones, M Zapatka, AM Stütz, T Zichner, J Weischenfeldt, ...
Cell 148 (1-2), 59-71, 2012
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
C Scholl, S Fröhling, IF Dunn, AC Schinzel, DA Barbie, SY Kim, SJ Silver, ...
Cell 137 (5), 821-834, 2009
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ...
Blood 119 (9), 2114-2121, 2012
Lenalidomide induces ubiquitination and degradation of CK1α in del (5q) MDS
J Krönke, EC Fink, PW Hollenbach, KJ MacBeth, SN Hurst, ND Udeshi, ...
Nature 523 (7559), 183-188, 2015
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ...
Blood 123 (21), 3247-3254, 2014
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
S Sander, L Bullinger, K Klapproth, K Fiedler, HA Kestler, TFE Barth, ...
Blood, The Journal of the American Society of Hematology 112 (10), 4202-4212, 2008
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further …
E Taskesen, L Bullinger, A Corbacioglu, MA Sanders, CAJ Erpelinck, ...
Blood, The Journal of the American Society of Hematology 117 (8), 2469-2475, 2011
A 17-gene stemness score for rapid determination of risk in acute leukaemia
SWK Ng, A Mitchell, JA Kennedy, WC Chen, J McLeod, N Ibrahimova, ...
Nature 540 (7633), 433-437, 2016
Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course
S Stilgenbauer, L Bullinger, P Lichter, H Döhner
Leukemia 16 (6), 993-1007, 2002
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
MG Kharas, CJ Lengner, F Al-Shahrour, L Bullinger, B Ball, S Zaidi, ...
Nature medicine 16 (8), 903-908, 2010
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
VI Gaidzik, L Bullinger, RF Schlenk, AS Zimmermann, J Röck, P Paschka, ...
Journal of Clinical Oncology 29 (10), 1364-1372, 2011
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
RF Schlenk, S Kayser, L Bullinger, G Kobbe, J Casper, M Ringhoffer, ...
Blood 124 (23), 3441-3449, 2014
The system can't perform the operation now. Try again later.
Articles 1–20